KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) EBT (2016 - 2025)

Resmed (RMD) has disclosed EBT for 17 consecutive years, with $496.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 18.6% year-over-year to $496.1 million, compared with a TTM value of $1.8 billion through Dec 2025, up 18.48%, and an annual FY2025 reading of $1.7 billion, up 32.64% over the prior year.
  • EBT was $496.1 million for Q4 2025 at Resmed, up from $446.8 million in the prior quarter.
  • Across five years, EBT topped out at $496.1 million in Q4 2025 and bottomed at $218.0 million in Q1 2021.
  • Average EBT over 5 years is $320.2 million, with a median of $275.2 million recorded in 2022.
  • The sharpest move saw EBT decreased 5.2% in 2023, then surged 61.23% in 2024.
  • Year by year, EBT stood at $237.3 million in 2021, then increased by 15.34% to $273.7 million in 2022, then dropped by 5.2% to $259.5 million in 2023, then skyrocketed by 61.23% to $418.3 million in 2024, then grew by 18.6% to $496.1 million in 2025.
  • Business Quant data shows EBT for RMD at $496.1 million in Q4 2025, $446.8 million in Q3 2025, and $458.1 million in Q2 2025.